Contrary to earlier reports in autoantibody heterogeneous [17] or not defined [34] cohorts of myositis patients, we did not find a difference in serum levels of BAFF between patients with DM and PM subgroups or higher BAFF levels in patients with ILD within the current autoantibody homogenous, anti-Jo-1-positive cohort. The gene discussed is TNFSF13B; the disease is dermatomyositis.